From actually toxic to highly specific - Novel drugs against poxviruses

Virology Journal

Volumn 4, Issue , 2007, Pages

  Sliva, Katja ^a   Schnierle, Barbara ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADENOSYLHOMOCYSTEINASE INHIBITOR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CANERTINIB; CIDOFOVIR; CYTIDINE TRIPHOSPHATE SYNTHETASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HEXADECYLOXYPROPYLCIDOFOVIR; IMATINIB; METISAZONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; OROTIDINE 5' PHOSPHATE DECARBOXYLASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; RIBAVIRIN; RIFAMPICIN; SMALLPOX VACCINE; ST 246; THIOSEMICARBAZONE; THIOSEMICARBAZONE DERIVATIVE; THYDIDYLATE SYNTHASE INHIBITOR; TUBERCULOSTATIC AGENT; U 1026; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ANTIBODY; VACCINIA VACCINE;

AFRICA; BACTERIAL INFECTION; BACTERIAL REPRODUCTION; BIOLOGICAL WARFARE; CANCER GROWTH; CELL METABOLISM; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; HOST CELL; HUMAN; INFECTION CONTROL; MOLECULAR BIOLOGY; MONKEYPOX VIRUS; NEPHROTOXICITY; NONHUMAN; ORTHOPOXVIRUS; PASSIVE IMMUNIZATION; POXVIRUS; POXVIRUS INFECTION; PROTEIN TARGETING; REVIEW; SMALLPOX; SMALLPOX VIRUS; VACCINATION; VIRUS INFECTION; VIRUS REPLICATION; VOMITING;

ANIMALS; ANTIVIRAL AGENTS; ENZYME INHIBITORS; HUMANS; MICE; ORTHOPOXVIRUS; PHOSPHOTRANSFERASES; POXVIRIDAE INFECTIONS; VIRAL PROTEINS; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); MONKEYPOX VIRUS; ORTHOPOXVIRUS; POXVIRIDAE; VARIOLA VIRUS;

EID: 33846467138     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-8     Document Type: Review

References (65)

1. A successful eradication campaign. Global eradication of smallpox. F Fenner, Rev Infect Dis 1982 4 916 930 6293036
2. Poxvirus dilemmas - monkeypox, smallpox, and biologic terrorism. JG Breman DA Henderson, N Engl J Med 1998 339 556 559 10.1056/NEJM199808203390811 9709051
3. Diagnosis and management of smallpox. JG Breman DA Henderson, N Engl J Med 2002 346 1300 1308 10.1056/NEJMra020025 11923491
4. Countermeasures to the bioterrorist threat of smallpox. PB Jahrling EA Fritz LE Hensley, Curr Mol Med 2005 5 817 826 10.2174/156652405774962326 16375715
5. Threats in bioterrorism. I: CDC category A agents. RG Darling CL Catlett KD Huebner DG Jarrett, Emerg Med Clin North Am 2002 20 273 309 10.1016/S0733-8627(02)00005-6 12120480
6. Bioterrorism as a public health threat. DA Henderson, Emerg Infect Dis 1998 4 488 492 9716981
7. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. YJ Hutin RJ Williams P Malfait R Pebody VN Loparev SL Ropp M Rodriguez JC Knight FK Tshioko AS Khan MV Szczeniowski JJ Esposito, Emerg Infect Dis 2001 7 434 438 11384521
8. Vaccinia virus replication. I. Requirement for the host-cell nucleus. DE Hruby LA Guarino JR Kates, J Virol 1979 29 705 715 107327
9. Poxvirus entry and membrane fusion. B Moss, Virology 2006 344 48 54 10.1016/j.virol.2005.09.037 16364735
10. Viral entry. SB Sieczkarski GR Whittaker, Curr Top Microbiol Immunol 2005 285 1 23 15609499
11. Vaccinia virus proteolysis - a review. CM Byrd DE Hruby, Rev Med Virol 2006 16 187 202 10.1002/rmv.499 16710840
12. Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. G Hiller K Weber, J Virol 1985 55 651 659 4020961
13. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. M Schmelz B Sodeik M Ericsson EJ Wolffe H Shida G Hiller G Griffiths, J Virol 1994 68 130 147 8254722
14. Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. J Tooze M Hollinshead B Reis K Radsak H Kern, Eur J Cell Biol 1993 60 163 178 8385018
15. Mechanism of vaccinia virus release and its specific inhibition by N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine. LG Payne K Kristenson, J Virol 1979 32 614 622 501802
16. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. R Blasco B Moss, J Virol 1992 66 4170 4179 1602540
17. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. RL Roper EJ Wolffe A Weisberg B Moss, J Virol 1998 72 4192 4204 9557708
18. Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. CM Sanderson F Frischknecht M Way M Hollinshead GL Smith, J Gen Virol 1998 79 ( Pt 6) 1415 1425 9634084
19. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. DC Quenelle DJ Collins ER Kern, Antimicrob Agents Chemother 2003 47 3275 3280 14506041 10.1128/AAC.47.10.3275-3280.2003
20. F.Fenner R.M.L.Bullet, Mousepox Philadelphia, Lippincott Raven, N.Nathanson I, Viral Pathogenesis. 1997
21. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. PL Earl JL Americo LS Wyatt LA Eller JC Whitbeck GH Cohen RJ Eisenberg CJ Hartmann DL Jackson DA Kulesh MJ Martinez DM Miller EM Mucker JD Shamblin SH Zwiers JW Huggins PB Jahrling B Moss, Nature 2004 428 182 5 10.1038/nature02331 15014500
22. F M F GW, Edward Jenner and vaccination New Haven, Yale University Press 1998 65 93
23. Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. VA Fulginiti A Papier JM Lane JM Neff DA Henderson, Clin Infect Dis 2003 37 241 250 10.1086/375824 12856217
24. Smallpox death in Britain challenges presumption of laboratory safety. N Hawkes, Science 1979 203 855 856 10.1126/science.419409 419409
25. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. CH Kempe C Bowles G Meiklejohn TO Berge L St Vincent BV BAabu S Govindarajan NR Ratnakannan AW Downie VR Murthy, Bull World Health Organ 1961 25 41 48 14455084
26. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. KJ Stittelaar J Neyts L Naesens G van Amerongen RF van Lavieren A Holy E De Clercq HG Niesters E Fries C Maas PG Mulder BA van der Zeijst AD Osterhaus, Nature 2006 439 745 748 10.1038/nature04295 16341204
27. Über eine neue, gegenTuberkelbazillen in vitro wirksame Verbindungsklasse. GR Domagk R Behnisch F Mietzch H Schmidt, Naturwissenschaften 1964 10
28. Studies on the chemotherapy of vaccinia virus. II. The activity of some thiosemicarbazones. D Hamre KA Brownlee R Donovick, J Immunol 1951 67 305 312 14888894
29. The antiviral and synergic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. DJ Bauer, Br J Exp Pathol 1955 36 105 114 14351641
30. Prophylactic treatment of small pox contacts with N-methylisatin beta-thiosemicarbazone (compound 33T57, marboran). DJ Bauer L St Vincent CH Kempe AW Downie, Lancet 1963 35 494 496 10.1016/S0140-6736(63)90230-7 14065422
31. Eczema vaccinatum treated with n-methylisatin beta-thiosemicarbazone. W Turner DJ Bauer RH Nimmo-Smith, Br Med J 1962 1 1317 1319 13923245
32. A history of the discovery and clinical application of antiviral drugs. DJ Bauer, Br Med Bull 1985 41 309 314 2996681
33. F Fenner JM White, medical virology New York, Academic Press 1970 190 190
34. Rifampicin inhibits the growth of some mammalian viruses. JH Subak-Sharpe MC Timbury JF Williams, Nature 1969 222 341 345 10.1038/222341a0 5782109
35. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. E De Clercq, Clin Microbiol Rev 2001 14 382 397 11292644 10.1128/CMR.14.2.382-397.2001
36. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. E De Clercq, Nucleosides Nucleotides Nucleic Acids 1994 13 1271 1295
37. S-Adenosyl-L-methionine-dependent macromolecule methyltransferases: potential targets for the design of chemotherapeutic agents. RT Borchardt, J Med Chem 1980 23 347 357 10.1021/jm00178a001 6991690
38. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. RO Baker M Bray JW Huggins, Antiviral Res 2003 57 13 23 10.1016/S0166-3542(02)00196-1 12615299
39. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. WC Magee KY Hostetler DH Evans, Antimicrob Agents Chemother 2005 49 3153 3162 16048917 10.1128/AAC.49.8.3153-3162.2005
40. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. RM Buller G Owens J Schriewer L Melman JR Beadle KY Hostetler, Virology 2004 318 474 481 10.1016/j.virol.2003.11.015 14972516
41. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. ER Kern DJ Collins WB Wan JR Beadle KY Hostetler DC Quenelle, Antimicrob Agents Chemother 2004 48 3516 3522 15328119 10.1128/AAC.48.9.3516-3522.2004
42. Oral drug and old vaccine renew smallpox bioterror debate. K Morris, Lancet Infect Dis 2002 2 262 10.1016/S1473-3099(02)00273-6 12062979
43. Orally available cidofovir derivative active against smallpox. J Bradbury, Lancet 2002 359 1041 10.1016/S0140-6736(02)08115-1 11937193
44. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. E De Clercq G Andrei J Balzarini P Leyssen L Naesens J Neyts C Pannecouque R Snoeck C Ying D Hockova A Holy, Nucleosides Nucleotides Nucleic Acids 2005 24 331 341 10.1081/NCN-200059772 16247948
45. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)- phosphonylmethoxyethyl]adenine) in HIV-infected patients. P Barditch-Crovo J Toole CW Hendrix KC Cundy D Ebeling HS Jaffe PS Lietman, J Infect Dis 1997 176 406 413 9237705
46. Orthopoxvirus targets for the development of antiviral therapies. MN Prichard ER Kern, Curr Drug Targets Infect Disord 2005 5 17 28 10.2174/1568005053174627 15777195
47. Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread. EJ Wolffe AS Weisberg B Moss, Virology 1998 244 20 26 10.1006/viro.1998.9103 9581774
48. Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus. JE Parkinson GL Smith, Virology 1994 204 376 390 10.1006/viro.1994.1542 8091668
49. Emerging drug targets for antiretroviral therapy. JD Reeves AJ Piefer, Drugs 2005 65 1747 1766 10.2165/00003495-200565130-00002 16114975
50. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. H Yang SK Kim M Kim PA Reche TJ Morehead IK Damon RM Welsh EL Reinherz, J Clin Invest 2005 115 379 387 15690085 10.1172/JCI200523220
51. The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication. AA Andrade PN Silva AC Pereira LP De Sousa PC Ferreira RT Gazzinelli EG Kroon C Ropert CA Bonjardim, Biochem J 2004 381 437 446 15025565 10.1042/BJ20031375
52. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. R Kerkela L Grazette R Yacobi C Iliescu R Patten C Beahm B Walters S Shevtsov S Pesant FJ Clubb A Rosenzweig RN Salomon RA Van Etten J Alroy JB Durand T Force, Nat Med 2006 12 908 916 10.1038/nm1446 16862153
53. Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin. J Sekiguchi JT Stivers AS Mildvan S Shuman, J Biol Chem 1996 271 2313 2322 10.1074/jbc.271.4.2313 8567695
54. Novel and specific inhibitors of a poxvirus type I topoisomerase. A Bond Z Reichert JT Stivers, Mol Pharmacol 2006 69 547 557 10.1124/mol.105.019067 16267207
55. Smart drugs: tyrosine kinase inhibitors in cancer therapy. LK Shawver D Slamon A Ullrich, Cancer Cell 2002 1 117 123 10.1016/S1535-6108(02)00039-9 12086869
56. Vaccinia virus B1 kinase: phenotypic analysis of temperature-sensitive mutants and enzymatic characterization of recombinant proteins. RE Rempel P Traktman, J Virol 1992 66 4413 4426 1602551
57. Vaccinia virus encodes an essential gene with strong homology to protein kinases. P Traktman MK Anderson RE Rempel, J Biol Chem 1989 264 21458 21461 2600076
58. Vaccinia virus gene H5R encodes a protein that is phosphorylated by the multisubstrate vaccinia virus B1R protein kinase. G Beaud R Beaud DP Leader, J Virol 1995 69 1819 1826 7853522
59. The punctate sites of accumulation of vaccinia virus early proteins are precursors of sites of viral DNA synthesis. A Domi G Beaud, J Gen Virol 2000 81 1231 1235 10769065
60. Vaccinia protein kinase 2: a second essential serine/threonine protein kinase encoded by vaccinia virus. S Lin SS Broyles, Proc Natl Acad Sci U S A 1994 91 7653 7657 8052637 10.1073/pnas.91.16.7653
61. Vaccinia virus morphogenesis is blocked by temperature-sensitive mutations in the F10 gene, which encodes protein kinase 2. S Wang S Shuman, J Virol 1995 69 6376 6388 7666539
62. Temperature-sensitive mutants with lesions in the vaccinia virus F10 kinase undergo arrest at the earliest stage of virion morphogenesis. P Traktman A Caligiuri SA Jesty K Liu U Sankar, J Virol 1995 69 6581 6587 7666563
63. NYVAC: a highly attenuated strain of vaccinia virus. J Tartaglia ME Perkus J Taylor EK Norton JC Audonnet WI Cox SW Davis HJ van der B Meignier M Riviere., Virology 1992 188 217 232 10.1016/0042-6822(92)90752-B 1566575
64. In vitro activity of potential anti-poxvirus agents. ER Kern, Antiviral Res 2003 57 35 40 10.1016/S0166-3542(02)00198-5 12615301
65. The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro. K Liu B Lemon P Traktman, J Virol 1995 69 7823 7834 7494294